Evaluation of quantitative FTD- Pneumocystis jirovecii kit for Pneumocystis infection diagnosis

Hoarau, Gautier; Gal, Solène Le; Zunic, Patricia; Poubeau, P.; Antok, Emmanuel; Jaubert, Julien; Nevez, Gilles; Picot, S.

doi:10.1016/j.diagmicrobio.2017.08.001

Cited by 15 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, multiple PCR assays have been developed for detection of P. jirovecii, most commonly utilizing primers for the mitochondrial large-subunit rRNA gene (mtLSU) or the multicopy major surface glycoprotein (msg) gene family (39)(40)(41)(42)(43)(44)(45)(46), and these assays appear to be 10 to 100 times more sensitive than microscopic detection of stained organisms. Several commercially available diagnostic PCR kits are approved for clinical use in a number of countries, primarily in Europe (47)(48)(49)(50); none are currently FDA approved for use in the United States.…”

Section: Introductionmentioning

confidence: 99%

A Molecular Window into the Biology and Epidemiology of Pneumocystis spp

2018

View full text Add to dashboard Cite

, a unique atypical fungus with an elusive lifestyle, has had an important medical history. It came to prominence as an opportunistic pathogen that not only can cause life-threatening pneumonia in patients with HIV infection and other immunodeficiencies but also can colonize the lungs of healthy individuals from a very early age. The genus includes a group of closely related but heterogeneous organisms that have a worldwide distribution, have been detected in multiple mammalian species, are highly host species specific, inhabit the lungs almost exclusively, and have never convincingly been cultured, making a fascinating but difficult-to-study organism. Improved molecular biologic methodologies have opened a new window into the biology and epidemiology of. Advances include an improved taxonomic classification, identification of an extremely reduced genome and concomitant inability to metabolize and grow independent of the host lungs, insights into its transmission mode, recognition of its widespread colonization in both immunocompetent and immunodeficient hosts, and utilization of strain variation to study drug resistance, epidemiology, and outbreaks of infection among transplant patients. This review summarizes these advances and also identifies some major questions and challenges that need to be addressed to better understand biology and its relevance to clinical care.

show abstract

Section: Introductionmentioning

confidence: 99%

A Molecular Window into the Biology and Epidemiology of Pneumocystis spp

2018

View full text Add to dashboard Cite

show abstract

“…Rutin tanıda ise daha çok Rt-PCR yöntemi gibi daha gelişmiş yöntemlerin kullanımı önerilmektedir. Kantitasyon olanağı sunması nedeniyle kolonizasyon/enfeksiyon ayrımında fikir veriyor olması yöntemin birincil üstünlüğü olarak gösterilmektedir [22][23][24] . Uygulamasının kolay ve hızlı bir yöntem olmasının yanı sıra kapalı sistem olması nedeniyle dışarıdan kontaminasyon riskini en aza indirmesi, yöntemin diğer avantajları olarak öne çıkmaktadır 8,22,23,[25][26][27] .…”

Section: Discussionunclassified

Pneumocystis jirovecii Laboratuvar Tanısında Gerçek Zamanlı Polimeraz Zincir Reaksiyonu Yönteminin Değerlendirilmesi

et al. 2020

View full text Add to dashboard Cite

“…Events were categorized as definite PJP if a patient exhibited signs or symptoms of pneumonia, there was presence of radiographic evidence of pneumonia and P jirovecii was identified in bronchoalveolar lavage (BAL) using microscopy (using a smear stained for P jirovecii) or polymerase chain reaction (PCR; >10 5 copies/mL) [31,32]. Events were categorized as possible PJP if a patient exhibited signs or symptoms of pneumonia, radiographic evidence of pneumonia was present, BAL was either not performed or the PCR result from the BAL yielded a low positive result (<10 5 copies/mL), no other cause of the pneumonia was found and the patient received PJP treatment for a minimum of 7 days (<7 days was accepted if the patient died within 7 days of starting PJP treatment).…”

Section: Pjpmentioning

confidence: 99%